Drug intelligence / Profile preview

TT-6-AmHap

Development stage: Preclinical
Lead developer: Oksana B. Tacks
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

TT-6-AmHap is a **heroin conjugate vaccine** designed to elicit an immune response that generates antibodies against heroin. It consists of the synthetic heroin hapten 6-AmHap (N-(7-acetamido-3-methyl-2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-9-yl)-3-mercaptopropanamide) covalently attached to the carrier protein tetanus toxoid (TT)[1][3]. The induced antibodies bind heroin in the bloodstream, preventing its psychoactive effects and heroin-induced behaviors, as demonstrated in multiple mouse studies for addiction and relapse prevention. The vaccine is administered with an adjuvant to enhance immunogenicity[3].

Other names: TT-6-AmHapTT6-AmHapTT 6-AmHap

Beyond the preview

Go deeper on TT-6-AmHap.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TT-6-AmHap.

Explore the full profile